Related Experiment Video
Updated: Jan 15, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Precision Epigenetic Reprogramming: CoREST Inhibition Sensitizes STK11-Mutant Tumors to Immune Checkpoint Blockade
1Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Abstract:
Loss-of-function mutations in STK11 (also known as LKB1) define a molecular subtype of non-small cell lung cancer that is resistant to immune checkpoint blockade therapy, partially owing to impaired T-cell infiltration and suppressed antigen presentation. Emerging evidence implicates epigenetic deregulation as a key driver of immune evasion in STK11-mutant tumors. In this issue of Cancer Research, Ahronian and colleagues identified the CoREST complex, via histone deacetylase 1, as a vulnerability that can be targeted pharmacologically to restore immune sensitivity in STK11-mutant tumors. The authors developed TNG260, a selective small-molecule CoREST inhibitor with favorable pharmacologic properties and reduced toxicity relative to pan-histone deacetylase inhibitors. In preclinical models of STK11-deficient non-small cell lung cancer, TNG260 reprograms the tumor epigenome to upregulate immune genes and synergizes with anti-PD-1 therapy to induce durable tumor regressions. Early clinical data from an ongoing trial (NCT05887492) show increased histone acetylation and CD8+ T-cell infiltration in patient tumors treated with TNG260 and pembrolizumab. This commentary places these findings in the broader context of epigenetic modulation of antitumor immune response. We also outline key questions for future investigation, including durability of immune response, tumor-type specificity, and biomarker strategies for patient selection and response monitoring. See related article by Ahronian et al., p. 3966.
Insights
Loss-of-function mutations in STK11 (also known as LKB1) cause resistance to immunotherapy in non-small cell lung cancer. Targeting the CoREST complex with TNG260 restores immune sensitivity and enhances anti-PD-1 therapy efficacy.
Area of Science:
- Oncology
- Immunology
- Epigenetics
Background:
- Loss-of-function mutations in STK11 (also known as LKB1) characterize a non-small cell lung cancer subtype resistant to immune checkpoint blockade.
- Immune evasion in STK11-mutant tumors is linked to epigenetic deregulation.
- Impaired T-cell infiltration and suppressed antigen presentation contribute to treatment resistance.
Purpose of the Study:
- To identify and pharmacologically target vulnerabilities in STK11-mutant non-small cell lung cancer to restore immune sensitivity.
- To evaluate the efficacy of a novel CoREST complex inhibitor, TNG260, in preclinical models and early clinical trials.
Main Methods:
- Identification of the CoREST complex, via histone deacetylase 1, as a therapeutic target.
- Development and testing of TNG260, a selective small-molecule CoREST inhibitor.
- Preclinical studies in STK11-deficient non-small cell lung cancer models and analysis of early clinical trial data (NCT05887492).
Main Results:
- TNG260 reprograms the tumor epigenome, upregulating immune genes in STK11-deficient models.
- TNG260 synergizes with anti-PD-1 therapy, leading to durable tumor regressions in preclinical studies.
- Early clinical data show increased histone acetylation and CD8+ T-cell infiltration in patients treated with TNG260 and pembrolizumab.
Conclusions:
- The CoREST complex is a druggable vulnerability in STK11-mutant non-small cell lung cancer.
- Pharmacological inhibition of CoREST can restore immune sensitivity and enhance immunotherapy efficacy.
- Further investigation is warranted regarding durability, tumor-type specificity, and biomarker strategies.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:22PI3K/mTOR/AKT Signaling Pathway
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:34Inhibition of Cdk Activity